Clovis Oncology Announces Proposed Secondary Offering of Shares of Common Stock by Selling Stockholders *No new shares of common stock being sold by the Company Business Wire BOULDER, Colo. -- December 2, 2013 Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that certain selling stockholders have commenced an underwritten public offering of 2,000,000 shares of the Company’s common stock which they recently acquired as consideration in connection with the Company’s acquisition of EOS (Ethical Oncology Science) S.p.A. All net proceeds from the sale of the common stock will be received by the selling stockholders. The Company will not receive any of the proceeds, and the total number of shares of its outstanding common stock will not change as a result of the offering. J. P. Morgan Securities LLC is acting as the sole manager for the offering. In addition, the selling stockholders intend to grant J. P. Morgan Securities LLC a 30-day option to purchase up to an additional 15 percent of the number of shares sold to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. This offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204. The shares are being offered by the selling stockholders pursuant to an effective shelf registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Clovis Oncology Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Contact: Clovis Oncology, Inc. Anna Sussman, 303-625-5022 firstname.lastname@example.org or Breanna Burkart, 303-625-5023 email@example.com
Clovis Oncology Announces Proposed Secondary Offering of Shares of Common Stock by Selling Stockholders
Press spacebar to pause and continue. Press esc to stop.